Metastatic biopsy programmes combined with advances in genomic sequencing have
provided new insights into the molecular landscape of castration-resistant prostate cancer …

Context Genomic testing is becoming increasingly important in patients with advanced
prostate cancer (PC) and is being incorporated in clinical practice to guide treatment …

Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses
considerable therapeutic challenges. Recent genetic and technological advances have …

Prostate cancer is the second leading cause of cancer deaths in the USA. The challenge in
managing castration-resistant prostate cancer (CRPC) stems not from the lack of therapeutic …

Understanding the molecular underpinnings of sensitivity to specific therapies will advance
the goal of precision medicine in prostate cancer (PCa). We identified three patients with …

Context Recent studies focused on the molecular characterization of metastatic prostate
cancer have identified genomic subsets and emerging resistance patterns. Detection of …

Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

Abstract Context Prostate cancer (PCa) is the most common noncutaneous malignancy and
the second leading cause of cancer mortality amongst men in the Western world. Up to 40 …

Purpose Evolving treatments, disease phenotypes, and biology, together with a changing
drug development environment, have created the need to revise castration-resistant prostate …

The genomics of primary prostate cancer differ from those of metastatic castration-resistant
prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer …